1. Shopper & Customer

How GoodRx is Evolving Its Reimbursement Approaches to Help Pharmacies and Consumers

Written by Posted on Less than 0 min read

Today’s guest post comes from Jim Sheninger, Pharmacy Strategy Officer at GoodRx.

Jim describes GoodRx’s emerging pharmacy contracting strategies. In addition to working through pharmacy benefit managers (PBMs), GoodRx now also contracts directly with Walgreens, CVS, and other national and regional pharmacies. These direct agreements are based on acqusition cost, which helps pharmacies stabilize gross margins while still providing low pricing for consumers. 

To learn more about GoodRx and its pharmacy partnerships, reach out to [email protected].

Read on for Jim’s insights.

Read more »

© 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Data & Insights

EXCLUSIVE: The 340B Program Reached $54 Billion in 2022—Up 22% vs. 2021

Drug Channels has just obtained new details on the size of the 340B Drug Pricing Program. I couldn’t wait to share the news, hence this special Sunday post. For 2022, discounted purchases under the 340B program reached a record $53.7 billion—an astonishing $9.8 billion (+22.3%) higher than its 2021 counterpart. The difference between list prices […]
2 min read
0
  1. Media & Marketing

Follow the 340B Prescription Dollar: How PBMs Profit from 340B Contract Pharmacies (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2025 live video webinar. During the webinar, I’ll provide an update the 340B program, which continues to defy gravity. Click here to see the original post. In my recent The 340B Drug Pricing Program: Trends, Controversies, and Outlook video webinar, I […]
2 min read
0
  1. Data & Insights

The Pivotal Role of Technology in Delivering Effective Patient Services

Today’s guest post comes from George Moore, Chief Information Technology Officer at CareMetx. As George explains using novel survey data, manufacturers view new technologies  as crucial for patient services. He then explains how digital technology, artificial intelligence (AI), and machine learning (ML) can be used to improve patient adherence and increase hub efficiencies. To learn […]
2 min read
0
  1. Shopper & Customer

GoodRx Announces New Way for Consumers To Access Sanofi’s Lantus for $35 at Over 70,000 Pharmacies Nationwide

Today’s guest post is from Dorothy Gemmell, Chief Commercial Officer at GoodRx. Dorothy explains the innovative new collaboration between GoodRx and Sanofi. Under the program, the out-of-pocket cost for Sanofi’s Lantus will be capped at $35 at any pharmacy that accepts GoodRx. This program will increase affordabiliy and broaden access for people living with diabetes. […]
2 min read
0
  1. Trends & External Forces

Medicare Part D in 2024: The Seven Largest Companies’ Preferred Pharmacy Networks and the Coming Collapse of the PDP Market

Open enrollment is under way for the 2024 Medicare Part D plans. Our exclusive analysis of Center for Medicare & Medicaid Services’ (CMS) data reveals that preferred cost sharing pharmacy networks will maintain their dominance as a component of Part D benefit design. For 2024: 94% of stand-alone Medicare Part D prescription drug plans (PDP) […]
2 min read
0
  1. Department: HBC

If Plan Sponsors Are So Unhappy with Their PBMs’ Transparency, Why Won’t They Change the Model?

A new survey of plan sponsors sheds light on their satisfaction with transparency at large and small pharmacy benefit managers (PBMs). As you will see, clients remain slightly more satisfied with the perceived transparency of smaller PBMs compared with the Big Three PBMs—CVS Caremark, Express Scripts, and Optum Rx. However, plan sponsors are dissatisfied with […]
2 min read
0
  1. Trends & External Forces

thINc’s Value-Based Care Summit

thINc’s Value-Based Care Summit Accelerating Healthcare’s Shift in the Move from Volume to Value In-Person Event December 5-6, 2023 in Washington, DC www.thinc350.com/VBCS Use promo code VBCDC to save $100. Register Today. View the Agenda Snapshot As healthcare stakeholders continue to prioritize the move to value-based care and aim to provide equitable access to care […]
4 min read
0
  1. Trends & External Forces

Anti-Obesity Drugs and The Coming Battle Over Utilization Management (video)

My recent Drug Channels Outlook 2024 webinar covered 12 key trends that will shape the commercial environment this year. The video excerpt below highlights my commentary on trend #2: the rapid growth of anti-obesity GLP-1 agonist drugs. As I explain, this growth will challenge payer and channel economics, while boosting profits for patient reimbursement hub […]
2 min read
0
  1. Trends & External Forces

NEW: The Drug Channels 2025 Video Webinar Series

Drug Channel Institute is pleased to announce The Drug Channels 2025 Video Webinar Series. Join Dr. Adam J. Fein for three live video webinars during 2025. These live, interactive events will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia. During these events, Dr. Fein will address the latest issues […]
3 min read
0
  1. Trends & External Forces

Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. Click here to see the original post from December 2023. Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a […]
2 min read
0
  1. Operations & Supply Chain

Five Crucial Trends Facing U.S. Drug Wholesalers in 2024 and Beyond

As regular readers of Drug Channels know, U.S. distribution and dispensing channels for prescription drugs are undergoing significant evolution and consolidation as the changing economics of pharmaceuticals challenge conventional business models. During this period of volatility, the core business model of the Big Three public pharmaceutical distribution companies—Cardinal Health, Cencora, and McKesson—remains intact. Put simply: […]
2 min read
0
  1. Trends & External Forces

Medicare Part D in 2024: Mapping Large Chains’ Position in 2024’s Preferred Pharmacy Networks

In Medicare Part D in 2024: The Seven Largest Companies’ Preferred Pharmacy Networks and the Coming Collapse of the PDP Market, I documented how those networks now dominate stand-alone Medicare Part D prescription drug plans (PDPs) and have become a major presence in Medicare Advantage prescription drug (MA-PD) plans. Today, I examine the seven largest […]
2 min read
0
  1. Data & Insights

Embedding Into the Provider’s Workflow is Key to a Specialty Drug’s Success

Today’s guest post comes from Nasir Ali, Chief Product Officer at CareMetx. Nasir reviews the cumbersome processes that affect providers’ preferences when prescribing a specialty drug to their patients. He believes that embedding the specialty drug initiation process into the provider’s workflow will benefit both patients and prescribers. Learn more by downloading CareMetx’s new 2024 […]
2 min read
0
  1. Trends & External Forces

Available for Preorder: The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

On March 19, 2024, Drug Channels Institute will release The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. This report—our fifteenth edition—remains the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing, reimbursement, and dispensing system. This unique, encyclopedic resource is your ultimate guide to the complex web of interactions within […]
3 min read
0
  1. Channel: Drug

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble?

The Humira biosimilar market just took another step forward—but remains far from its ideal state. Last week, Cigna’s Express Scripts announced that it that will follow CVS Health’s CVS Caremark business and remove Humira from its largest commercial formulary in favor of multiple biosimilars. Below, we review the 18 products competing with Humira—including four private-label […]
2 min read
0
  1. Holiday & Events

Drug Channels News Roundup, October 2024: Humira Price War Update, PA vs. Providers, IRA vs. Physicians, My AI Podcast, New DCI Jobs, and Dr. G on Copayments

Eeek! It’s time for Drug Channels’ Halloween roundup of terrifying tales to share with your ghoulish fiends. This month’s tricks and treats: Spooky! Blue Shield of California frightens away the gross-to-net bubble with its Humira biosimilar strategy Vampiric! Prior authorization sinks its fangs into providers’ time Wicked! How the IRA will put a stake through […]
2 min read
0
  1. Trends & External Forces

The 340B Program Reached $66 Billion in 2023—Up 23% vs. 2022: Analyzing the Numbers and HRSA’s Curious Actions

Reality has again failed to support the spin surrounding the 340B Drug Pricing Program. For 2023, discounted purchases under the 340B program reached a record $66.3 billion—an astounding $12.6 billion (+23.4%) higher than its 2022 counterpart. The gross-to-net difference between list prices and discounted 340B purchases also grew, to $57.8 billion (+$5.5 billion). 340B purchases […]
2 min read
0
  1. Data & Insights

White Bagging Update 2024: Providers’ Pushback Preserves Buy-and-Bill (rerun)

This week, I’m rerunning some popular posts while I prepare for tomorrow’s Drug Channels Outlook 2025 live video webinar. During the webinar, I’ll share some thoughts on how vertical integration will affect the buy-and-bill channel. Click here to see the original post from September 2024. Time for DCI’s annual update on the channels for provider-administered […]
2 min read
0
  1. Data & Insights

Breaking Down Barriers: Helping Patients Get Therapies Quickly

Today’s guest post comes from Kevin Kettler, President of CoverMyMeds. Kevin asks: What if there were no barriers across the therapy access and reimbursement process? In his view, eliminating barriers requires a combination of expert insight, actionable data, and simplification of the providers’ experiences. Click here to learn more about CoverMyMeds’ comprehensive technology solutions. Meet […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, October 2023: CVS & Humira Biosimilars, GLP-1 G2N Bubble, 340B Abuses, Rite Aid’s Endgame, Mark Cuban Update, and an Epic Meetup

Zoinks! It’s time for a super-sized Halloween roundup of wicked Drug Channels’ tales. This month’s tricks and treats: Spooky! CVS Health frightens all but one Humira biosimilar maker away from its formulary. Creepy! The gross-to-net bubble for anti-obesity GLP-1 drugs walks among us. Grotesque! Penn Medicine gorges on the 340B program. Vampiric! Rite Aid’s many […]
2 min read
0
Next